Abstract

BackgroundMicroRNAs (miRNAs) play key roles in tumorigenesis and progression of gastric cancer (GC). miR-1269 has been reported to be upregulated in several cancers and plays a crucial role in carcinogenesis and cancer progression. However, the biological function of miR-1269 in human GC and its mechanism remain unclear and need to be further elucidated.MethodsThe expression of miR-1269 in GC tissues and cell lines was detected by quantitative real-time PCR (qRT-PCR). Target prediction programs (TargetScanHuman 7.2 and miRBase) and a dual-luciferase reporter assay were used to confirm that Ras-association domain family 9 (RASSF9) is a target gene of miR-1269. The expression of RASSF9 was measured by qRT-PCR and Western blotting in GC tissues. MTT and cell counting assays were used to explore the effect of miR-1269 on GC cell proliferation. The cell cycle and apoptosis were measured by flow cytometry. RASSF9 knockdown and overexpression were used to further verify the function of the target gene.ResultsWe found that miR-1269 expression was upregulated in human GC tissues and cell lines. The overexpression of miR-1269 promoted GC cell proliferation and cell cycle G1-S transition and suppressed apoptosis. The inhibition of miR-1269 inhibited cell growth and G1-S transition and induced apoptosis. miR-1269 expression was inversely correlated with RASSF9 expression in GC tissues. RASSF9 was verified to be a direct target of miR-1269 by using a luciferase reporter assay. The overexpression of miR-1269 decreased RASSF9 expression at both the mRNA and protein levels, and the inhibition of miR-1269 increased RASSF9 expression. Importantly, silencing RASSF9 resulted in the same biological effects in GC cells as those induced by overexpression of miR-1269. Overexpression of RASSF9 reversed the effects of miR-1269 overexpression on GC cells. Both miR-1269 overexpression and RASSF9 silencing activated the AKT signaling pathway, which modulated cell cycle regulators (Cyclin D1 and CDK2). In contrast, inhibition of miR-1269 and RASSF9 overexpression inhibited the AKT signaling pathway. Moreover, miR-1269 and RASSF9 also regulated the Bax/Bcl-2 signaling pathway.ConclusionsOur results demonstrate that miR-1269 promotes GC cell proliferation and cell cycle G1-S transition by activating the AKT signaling pathway and inhibiting cell apoptosis via regulation of the Bax/Bcl-2 signaling pathway by targeting RASSF9. Our findings indicate an oncogenic role of miR-1269 in GC pathogenesis and the potential use of miR-1269 in GC therapy.

Highlights

  • MicroRNAs play key roles in tumorigenesis and progression of gastric cancer (GC). miR-1269 has been reported to be upregulated in several cancers and plays a crucial role in carcinogenesis and cancer progres‐ sion

  • MiR‐1269 facilitates GC cell growth, induces cell cycle transition and inhibits apoptosis To explore the role of miR-1269 in human GC, AGS/ MKN-45 cells were transfected with the miR-1269 precursor expression vector, a control empty vector, miR1269 antisense oligonucleotides, or the negative control. quantitative realtime PCR (qRT-PCR) was conducted to detect the expression of miR1269 after treatment. miR-1269 expression was markedly increased in cells transfected with the miR-1269 vector compared to cells transfected with the control vector (p < 0.01); there were no significant differences between the anti-miR-1269 group and the anti-miRControl group (Fig. 2a, b)

  • Our findings demonstrated that miR-1269 promoted GC cell proliferation, induced G1-S cell cycle transition and suppressed apoptosis

Read more

Summary

Introduction

MicroRNAs (miRNAs) play key roles in tumorigenesis and progression of gastric cancer (GC). miR-1269 has been reported to be upregulated in several cancers and plays a crucial role in carcinogenesis and cancer progres‐ sion. MicroRNAs (miRNAs) play key roles in tumorigenesis and progression of gastric cancer (GC). MiR-1269 has been reported to be upregulated in several cancers and plays a crucial role in carcinogenesis and cancer progres‐ sion. The biological function of miR-1269 in human GC and its mechanism remain unclear and need to be further elucidated. Despite evident advances in the treatment of early GC, including radiotherapy, chemotherapy, surgical techniques, adjuvant therapy, molecular targeted therapy and earlier diagnosis, the 5-year survival rate of patients with advanced GC remains only 5–20% [6, 7]. The exact molecular mechanisms relevant to GC development and progression remain unclear. It is of great significance to further elucidate the potential pathogenesis of GC and look for new therapeutic targets for this disease

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call